Navigation Links
NIST trumps the clumps: Making biologic drugs safer
Date:7/23/2008

Scientists at the National Institute of Standards and Technology (NIST) have developed a technique to measure the formation of clumps of proteins in protein-based pharmaceuticals. This first systematic study* clarifies the conditions under which scientists can be assured that their instruments are faithfully measuring the formation of protein aggregates, a major concern because of its impact on quality control and safety in biologic drug manufacturing.

Proteins, a main constituent of many new drugs, are large molecules that have a tendency to stick to each other and form clumps during their manufacture. These clumps have been associated with severe immune responses. In at least one case, the inadvertent creation of protein clumps during the processing of a drug to treat anemia caused an immune reaction in about 250 patients that destroyed their ability to produce red blood cells. Those patients now have to receive blood transfusions every few days to replenish these vital cells.

Events such as this led the Food and Drug Administration to call for the development of sensitive and rapid measurement tools that can detect aggregation of protein drugs during the manufacturing phase. To address the problem, NIST researchers hit upon the idea of adapting a technique known as electrospray differential mobility analysis (ES-DMA). Commonly used to size soot and other aerosols, ES-DMA uses an electric current to vaporize a solution of proteins into tiny charged water droplets, each containing a single protein molecule or protein aggregate. Once these droplets evaporate, the charged proteins and protein aggregates are drawn into an oppositely charged tube. By making controlled adjustments to the voltage of the tube and the velocity of the air flowing through it, researchers can collect particles of a specific size, allowing the proteins and protein aggregates to be precisely sorted and counted.

The NIST team adapted the technique for biopharmaceutical applications. According to researcher Leonard Pease, ES-DMA is tricky to get right, but the NIST team was able to define the conditions needed to electrospray proteins and protein aggregates reliably and repeatedly. NIST scientists favor ES-DMA for its ability to quickly resolve particle sizes differing by as little as 0.2 nanometers, to provide a direct measure of particle size distributions, and to accept bioreactor samples with significantly reduced preparation requirements.

In addition to sizing proteins, Pease said the technique could also be used to accurately size many different types of particles used in medicine, such as the viruses used in the human papillomavirus (HPV) vaccine and gene therapy. The adaptation of this technology is just one of many excellent examples of how NIST seeks out and works with U.S. industry, says Willie E. May, director of the NIST Chemical Science and Technology Laboratory.


'/>"/>

Contact: Mark Esser
mark.esser@nist.gov
301-975-8735
National Institute of Standards and Technology (NIST)
Source:Eurekalert

Related biology news :

1. Coal and black liquor can produce energy from papermaking
2. Another type of nanotube, a how-to guide to making bamboo-structured carbon nanotubes
3. GBIF making the search for biodiversity research resources easier
4. Making sense of antisense microRNAs
5. Is that sea otter stealing your lunch -- or making it?
6. LSU scientist finds evidence of rain-making bacteria
7. Making sure the wonder materials dont become the wonder pollutant
8. Findings a step toward making new optical materials
9. Research suggests parts of UK could be too hot for wine-making by 2080
10. Research suggests parts of UK could be too hot for wine making by 2080
11. Small protein may have big role in making more bone and less fat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):
(Date:5/26/2017)... ... May 25, 2017 , ... Throughout this webinar, participants will ... process development and economic goals were achieved in both industry and academic settings. ... system, along with techniques for scaling production of mesenchymal stem cells (MSCs) and ...
(Date:5/24/2017)... BOUNTIFUL, Utah (PRWEB) , ... May 24, 2017 ... ... announces the selection and implementation of CLEARAS Water Recovery’s Advanced Biological Nutrient Recovery ... a key component of a $24 million plant upgrade to sustainably meet current ...
(Date:5/24/2017)... May 23, 2017 As Ebola resurfaces in the ... deaths and 20 suspected cases now reported, a new analysis ... database, showed a correlation between the 2014 and 2017 outbreaks ... rose sharply in 2012-13, which preceded the 2014 outbreak. An ... Ebola gene Replikin counts in 2014-15, which again precedes the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a ... anniversary, marking the occasion with a strong presence at Bio-IT World Conference & ... further extends an invitation to all attendees to view posters on the ...
Breaking Biology Technology: